How will coronavirus hit U.S. drugmakers? Depends what kind of drugmaker you are

There’s no doubt the ongoing novel coronavirus outbreak poses a major threat to people’s health. But for U.S. biopharma companies, the impact on their businesses may be mixed, Moody’s said.

If the virus persists long enough, branded drugmakers may see decreased demand for their innovative drugs in China, the credit rating service said in a report on Wednesday. But on the other hand, the global spread of the virus could lead to government stockpiling of certain drugs such as antivirals.